Results 181 to 190 of about 137,029 (384)

THU0230 Anti-tnfa therapy with infliximab in the treatment of hla b27 associated acute anterior uveitis [PDF]

, 2001
Yosuf El‐Shabrawi, Josef Hermann
openalex   +1 more source

Epidemiology and the cost burden of hospitalized pediatric‐onset inflammatory bowel disease in China: A national database study

Pediatric Investigation, EarlyView.
This study provides insights into the clinical characteristics and cost burden of pediatric‐onset inflammatory bowel disease (PIBD) and very early onset IBD (VEO‐IBD) in China. Hospitalizations for PIBD, particularly Crohn's disease, are increasing. Guidelines and health insurance policies can help mitigate the cost burden.
Xiaolu Nie, Jing Li, Hui Xu, Fang Hu, Xiaolin Ye, Mengmeng Yu, Guoshuang Feng, Yueping Zeng, Xin Ni, Jie Wu, Xiaoxia Peng, the Futang Research Center of Pediatric Development (FRCPD)   +11 more
wiley   +1 more source

CLINICAL EXAMPLES OF ANTICYTOKINE TREATMENT OF CHILDREN WITH CROHN DISEASE

Вопросы современной педиатрии, 2011
Infliximab is one of the first biological agents that has proven its efficacy in Crohn’s disease treatment in various multicenter randomized studies. Anticytokine treatment with infliximab allows to reach clinical, lab and endoscopic remission and secure
M.M. Venediktova, E.G. Tsimbalova, А.S. Potapov   +2 more
doaj  

TNF microsatellite polymorphism does not predict response to infliximab in patients with Crohn's disease

, 2000
James F. Marion, Carol Bodian, Toy Lisa, Mark L. Chapman, Ellen Scherl, Daniel H. Present   +5 more
openalex   +1 more source

THU0235 Treatment of refractory posterior uveitis with anti-tnf-alfa (infliximab) [PDF]

, 2001
A Bañares, Esperanza Pato, Lydia Abásolo, Pilar Macarrón, García Hernández, J. A. Jover, Benjamín Fernández‐Gutiérrez   +6 more
openalex   +1 more source

Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers

Small Methods, EarlyView.
Oral delivery is a preferred administration route for many clinical applications, valued for its strong patient compliance. In this review, how nanoparticles are engineered and deployed to overcome the gastrointestinal barriers that impede clinical translation of oral delivery formulations is examined.
Luke J. Kubiatowicz, Nima Pourafzal, Audrey T. Zhu, Zhongyuan Guo, Ronnie H. Fang, Liangfang Zhang   +5 more
wiley   +1 more source

Short term infliximab toxicity in crohn's disease

, 2000
Lisa Toy, James F. Marion, Ellen Scherl, Mark L. Chapman, Daniel H. Present   +4 more
openalex   +1 more source

Severe Pneumococcal Pneumonia Following Treatment with Infliximab for Crohn's Disease [PDF]

, 2001
Marc Alain Ritz, Res Jost
openalex   +1 more source

Volumetric Changes in Perianal Fistulizing Crohn's Disease Measured by Magnetic Resonance Is Feasible and Could Be a Potential Biomarker to Predict Clinical Outcomes

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aim Changes in 3D volumetry of perianal fistulas in patients with Crohn's disease (CD) measured by MRI could be an imaging biomarker of interest. The objective of the study was to determine the value of volumetric changes in CD perianal fistulas after medical treatment to predict outcomes.
Berta Caballol, Ingrid Ordás, Carolina Saavedra, Julia Saidman, Maria Carmen Masamunt, Marta Gallego, Rebeca Barastegui, Agnès Fernández‐Clotet, Alex Menys, Julian Panés, Elena Ricart, Jordi Rimola   +11 more
wiley   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj